Web Exclusives

A comprehensive analysis of immune checkpoints in gastric adenocarcinoma found that ICOSLG and CD70 are associated with immune infiltration and may potentially serve as prognostic biomarkers. Read More ›

Phase 2 study results of second-line trastuzumab deruxtecan use in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer revealed an antitumor response. Read More ›

To ensure optimal treatment selection and outcomes, differentiating between COVID-19 infection and interstitial lung disease is critical. Read More ›

Efficacy of osimertinib as adjuvant therapy was demonstrated in ADAURA, a randomized, double-blind, placebo-controlled trial. Read More ›

Positive findings from this study support channeling additional resources into telemedicine care for lung cancer, and into future randomized controlled trials to verify effectiveness. Read More ›

The COVID-19 pandemic has highlighted how critical it is to maintain resilience and flexibility of the healthcare system and healthcare providers. Read More ›

Clinical data are highlighted, providing an understanding of the benefits of treatment with tyrosine kinase inhibitors. Read More ›

Emerging evidence suggests PARP inhibitors have the potential to revolutionize the treatment of ovarian cancer. Read More ›

Patients with advanced ovarian cancer may be eligible to receive frontline maintenance treatment with olaparib plus bevacizumab. Read More ›

Ovarian cancer survivors frequently use adaptive and problem-focused coping strategies. During the COVID-19 pandemic, virtual technology has played a key role in shaping and determining these strategies. Read More ›